These in vivo results suggest that TEPP-46’s therapeutic effect on periodontitis comes from inhibiting PKM2 nuclear translocation, thereby reducing STAT3 phosphorylation and subsequently reducing osteoclastogenesis. The gene discussed is PKM; the disease is periodontitis.